Merck and Moderna’s cancer vaccine data leak precedes official Phase 3 results release

Results from the Phase 3 trial of Moderna and Merck’s therapeutic cancer vaccine were made public on Thursday after an earlier leak of the data.

The vaccine, called intismeran autogene, is being evaluated as a treatment for cancer and has attracted considerable attention from the industry.

Both companies noted that the trial data were released following the leak, but no specific efficacy or safety outcomes were disclosed in the brief report.